Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Energy Restriction in T2DM with MAFLD
NCT07272343Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Feb 2023
- Primary completion
- Jun 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in type 2 diabetes mellitus (T2DM), metabolic associated fatty liver disease (MAFLD), sponsored by The Second Affiliated Hospital of Nanchang University. Started Feb 2023; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT07272343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272343.